Canadian cannabis producer Aurora Cannabis is pressing ahead with its UK expansion, announcing the acquisition of Internode Pharma and HAP Pharma for £2.1 million in cash. The deal comes just days after Aurora urged shareholders to reject an unsolicited $4.00-per-share takeover bid from US rival Curaleaf.
The two UK businesses add an import-and-distribution site and a “virtual pharmacy” in England, giving Aurora a more direct route from cultivation to delivering medical cannabis to patients. For a company that has struggled to turn consistent profits, the move signals a focus on building out a regulated, higher-margin medical channel rather than relying solely on recreational sales.
Why the UK matters for cannabis companies
The UK is one of the largest potential markets for medical cannabis in Europe, but it remains tightly regulated. Companies that can navigate the import and prescription process—and build relationships with clinicians and pharmacies—stand to gain a foothold in a market that is still early in its development. Aurora’s purchases are small in dollar terms, but they are strategically placed: an import-and-distribution site handles the logistics of bringing cannabis into the country, while a virtual pharmacy can connect directly with patients and prescribers.
This is not just about expansion for its own sake. The timing is telling. Aurora is in the middle of a public battle with Curaleaf, which has made a $4.00-per-share cash offer for the company. By announcing these bolt-on acquisitions, Aurora is strengthening its case that it can create more value as an independent company than by selling at the current bid.
What the deal means for Curaleaf’s bid
For Curaleaf, the acquisitions complicate the takeover math. When a bidder targets a company that is actively making deals, it has to underwrite the new integration and regulatory risks. The buyer may need to reassess the value of the target, especially if the acquisitions change the company’s revenue mix or add debt. In this case, the £2.1 million price tag is modest, but the strategic implications could be larger.
Curaleaf has not yet commented on the new acquisitions. The company’s offer remains on the table, and Aurora’s board has advised shareholders to take no action. The situation echoes other recent cross-border takeover attempts in the cannabis sector, where valuations have been volatile and regulatory hurdles are common.
What it means for investors
For everyday investors, this is a reminder that M&A battles can be unpredictable. When a company rejects a bid, it is betting that it can deliver more value on its own. That bet may pay off, or it may not. Aurora’s management is essentially saying: “We can build a profitable medical cannabis business in the UK, and that will be worth more than $4.00 per share.”
Investors should watch a few things. First, how Curaleaf responds—whether it raises its offer, walks away, or launches a hostile tender. Second, whether Aurora can actually integrate these UK assets and show progress toward profitability. Third, the broader regulatory environment for cannabis in Europe, which remains uncertain.
It’s also worth noting that Aurora’s shares have been volatile, and the bid price represents a premium to where the stock traded before the offer. Shareholders who believe in the UK strategy may want to hold on, while those who are skeptical may prefer to take the cash. But that is a personal decision, not one to be made lightly.
For context, the Canadian cannabis market has been tough for producers, with oversupply and price compression. Many companies have pivoted to medical and international markets to find better margins. Aurora’s move is in line with that trend, but it remains to be seen if it will be enough to fend off Curaleaf.
As the situation develops, investors should keep an eye on any updates from either company. The next few weeks could be decisive.
